B
Bull
Bull · 25%DMAA
$10.91
情境價格
$10.750
-0.010 (-0.09%)收盤時
Loading chart…
- High
- 10.750
- Open
- 10.750
- VWAP
- 10.75
- Vol
- 4.23K
- Mkt Cap
- —
- Low
- 10.740
- Amount
- 45.44K
- EV/EBITDA, TTM
- 0.00
Drugs Made In America Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to focus its search for businesses in the pharmaceutical industry. The Company has neither engaged in any operations nor generated any revenues.
AI analysis of Drugs Made In America Acquisition Corp (DMAA)
holdCurrently, DMAA is not a strong buy due to its high P/E ratio of 55.63 and a low current ratio of 0.02, indicating potential liquidity issues. The RSI is at 61.24, suggesting it is nearing overbought territory, which may limit upside potential in the short term.
估值指標
The current forward P/E ratio for Drugs Made In America Acquisition Corp (DMAA) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for DMAA
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding DMAA
DMAA FAQ — answered by Alphio AI
Drugs Made In America Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to focus its search for businesses in the pharmaceutical industry. The Company has neither engaged in any operations nor generated any revenues. It operates in the Financials sector.
Currently, DMAA is not a strong buy due to its high P/E ratio of 55.63 and a low current ratio of 0.02, indicating potential liquidity issues. The RSI is at 61.24, suggesting it is nearing overbought territory, which may limit upside potential in the short term.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。